G-protein coupled receptor ligands and methods
AssigneeSchering Corporation
InventorsYing Jiang, Fang Liang Zhang, Nicholas J. Murgolo, Lin Luo, Jason S. Simon
Life of this patent
Estimating the term…
Abstract
The present invention relates to RF-amide peptides and their use for treating, preventing and curing neurological and metabolic medical disorders. The invention also relates to methods for modulating a G-protein coupled receptor and for identifying substances which modulate the receptor.
Claims25
A method for identifying an agonist or antagonist of an SP9155 receptor, comprising:
- (a) contacting the SP9155 receptor or a functional fragment thereof, in the presence of a known amount of labeled SP9155 receptor ligand, with a sample to be tested for the presence of said agonist or antagonist;
- and
- (b) measuring the amount of the ligand specifically bound to the receptor;
- whereby the sample is identified as containing an antagonist or an agonist by measuring substantially reduced binding of the labeled ligand to the receptor, compared to what would be measured in the absence of the sample.
A method for identifying an agonist or antagonist of an SP9155 receptor comprising:
- (a) contacting a cell expressing the SP9155 receptor or a functional fragment thereof, in the presence of a known amount of SP9155 receptor ligand, with a sample to be tested for the presence of said agonist or antagonist;
- and
- (b) measuring calcium mobilization by the cell;
- whereby the sample is identified as containing an antagonist by measuring substantially reduced calcium mobilization compared to what would be measured in the absence of the sample and whereby the sample is identified as containing an agonist by measuring substantially increased calcium mobilization compared to what would be measured in the absence of the sample.
A method for making a polypeptide comprising culturing a host cell comprising a recombinant vector which vector comprises a nucleic acid encoding an antigenic polypeptide comprising 7 or more contiguous amino acids from SEQ ID NO:
- 4 or from SEQ ID NO:
- 13 under conditions in which the nucleic acid is expressed.
A method for forming a complex between an antigenic peptide comprising 7 or more contiguous residues of an amino acid sequence selected from SEQ ID NOs:
- 4 and 13 and an antibody molecule which specifically binds said peptide comprising contacting said peptide with said antibody molecule.
A method for treating or preventing a medical condition in a subject mediated by the SP9155 receptor comprising administering, to the subject, a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof which specifically binds to a polypeptide comprising 7 or more contiguous amino acids from SEQ ID NO:
- 4 or from SEQ ID NO:
- 13 and a pharmaceutically acceptable carrier.
An isolated antigenic polypeptide comprising 7 or more contiguous residues of an amino acid sequence selected from SEQ ID NOs:
- 4 and 13.
An isolated polypeptide comprising an amino acid sequence selected from SEQ ID NOs:
- 4-11 and 13-18
Dependencies are inferred from the claim text.